PE-22-28 Dosage: 200-400mcg Community Protocol

The community PE-22-28 protocol is 250 mcg SubQ in the morning, 3-4 times a week, for 8 weeks on and 8 weeks off. Other reports describe 200-400 mcg intranasally once daily, or 100-200 mcg SubQ daily, with self-reports capping total intake under 600 mcg. None of these numbers comes from a trial: PE-22-28 has never been dosed in a human study.

Research-context information only. PE-22-28 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

PE-22-28 is a 7-amino-acid spadin fragment that blocks the TREK-1 potassium channel. This guide covers the community protocols, both routes, and the syringe math per vial size.

Quick Reference: Community Protocol

Note: PE-22-28 has no clinical dosing literature — no Phase 1, no pharmacokinetics, no human safety data. Every value below is a reported figure for a compound whose entire efficacy record is mouse behavior.

Other reported figures: 200-400 mcg intranasally once daily, or 100-200 mcg SubQ once daily (4 units at 200 mcg, same dilution), in 4-8 week runs, with self-reports keeping total intake under 600 mcg.

All figures above are reported practice, not clinical dosing.

Cycling Details

The community protocol runs 8 weeks on, 8 weeks off at 3-4 doses a week; other reports describe daily dosing in 4-8 week runs followed by breaks. Both mirror the general research-peptide pattern rather than anything PE-22-28-specific: the published animal work used 4-day sub-chronic treatment (Djillani et al., 2017), and no study — animal or otherwise — has examined longer administration.

The reported rationale for the morning-only, sub-600 mcg shape: self-reports describe lethargy at higher doses, so protocols hold the dose down and keep it early in the day.

Routes of Administration

Intranasal. Common in self-reports, though not the community protocol's route — typically 200-400 mcg once daily from a sprayer after reconstitution. No published human data supports or quantifies nasal absorption for this peptide.

Subcutaneous injection. The community protocol's route: 250 mcg, 3-4 times a week. Other reports describe 100-200 mcg daily. The published mouse work used systemic administration, which is the loose community rationale for the injectable route.

Oral. Not described — as a peptide it would be expected to degrade in digestion, and no oral form or report exists.

Reconstitution Quick Reference

10 mg vial + 2 mL BAC = 5 mg/mL. 250 mcg = 0.05 mL = 5 units; 200 mcg = 0.04 mL = 4 units. The dilution reflects how community protocols describe the math, not a set of instructions to follow.

Community protocols describe swirling gently rather than shaking, refrigerating at 2-8°C, and using within 3-4 weeks.

For the full mixing walkthrough, see the PE-22-28 Reconstitution Guide.

Ready to buy? Compare current sources on our best PE-22-28 page (vendor links are affiliate links), or browse all coupon codes for up to 50% off.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

They don't come from trials — that's the honest answer. The only published dosing context is preclinical: the study introducing PE-22-28 demonstrated TREK-1 inhibition at an IC50 of 0.12 nM and antidepressant behavioral effects in mice after 4-day treatment (Djillani et al., 2017), building on the spadin work before it (Mazella et al., 2010).

Community protocols back-form the human figures from vendor sizing and self-experimentation, not from any mouse-to-human scaling published for this compound. The 250 mcg community figure, the 200-400 mcg intranasal range, the morning timing, and the sub-600 mcg ceiling are all convention that hardened through forum repetition. That is worth sitting with before treating the numbers as established.

Stacking Protocols

PE-22-28 appears in community nootropic rotations alongside better-documented peptides:

These are reported combinations with no published interaction data — for an un-trialed compound, stacking adds a second unknown on top of the first.

Side Effects & Safety

• No human safety data exists — this is the entire safety profile
• Lethargy at higher doses is the most repeated self-report, and the stated reason for the sub-600 mcg community ceiling
• Mouse studies reported no cardiac or pain-threshold effects at effective doses — the research group's own selectivity claim, not independently replicated
• Nasal irritation reported occasionally with intranasal use
• TREK-1 sits in cardiac and pain pathways; the theoretical concern is inherent to the target

mg to Units Conversion

On a standard U-100 insulin syringe, each unit is 0.01 mL. The conversions below reflect the dilutions documented in community protocols — they report how the math is described, not a dosing schedule.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more water for larger, easier-to-measure draws.

The same math, interactive — pick a vial size and dose to see the exact units to draw and how many doses a vial yields: